Berkeley Home Health Limited 08781493 false 2024-04-01 2025-03-31 2025-03-31 The principal activity of the company is that of an intermediate parent company and the provision of domiciliary care services. Digita Accounts Production Advanced 6.30.9574.0 true true true false true false false false false false false 08781493 2024-04-01 2025-03-31 08781493 2025-03-31 08781493 bus:OrdinaryShareClass1 2025-03-31 08781493 bus:Consolidated 2025-03-31 08781493 core:AcceleratedTaxDepreciationDeferredTax 2025-03-31 08781493 core:ProvisionsDeferredTax 2025-03-31 08781493 core:RetainedEarningsAccumulatedLosses 2025-03-31 08781493 core:ShareCapital 2025-03-31 08781493 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 08781493 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2025-03-31 08781493 core:Goodwill 2025-03-31 08781493 core:PatentsTrademarksLicencesConcessionsSimilar 2025-03-31 08781493 core:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments 2025-03-31 08781493 core:WithinOneYear 2025-03-31 08781493 core:FurnitureFittingsToolsEquipment 2025-03-31 08781493 core:OtherPropertyPlantEquipment 2025-03-31 08781493 bus:FRS102 2024-04-01 2025-03-31 08781493 bus:Audited 2024-04-01 2025-03-31 08781493 bus:FullAccounts 2024-04-01 2025-03-31 08781493 bus:RegisteredOffice 2024-04-01 2025-03-31 08781493 bus:Director1 2024-04-01 2025-03-31 08781493 bus:OrdinaryShareClass1 2024-04-01 2025-03-31 08781493 bus:Consolidated 2024-04-01 2025-03-31 08781493 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 08781493 1 2024-04-01 2025-03-31 08781493 core:FinancialGuarantees 2024-04-01 2025-03-31 08781493 core:RetainedEarningsAccumulatedLosses 2024-04-01 2025-03-31 08781493 core:ShareCapital 2024-04-01 2025-03-31 08781493 core:ComputerSoftware 2024-04-01 2025-03-31 08781493 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-04-01 2025-03-31 08781493 core:Goodwill 2024-04-01 2025-03-31 08781493 core:PatentsTrademarksLicencesConcessionsSimilar 2024-04-01 2025-03-31 08781493 core:LandBuildingsUnderOperatingLeases 2024-04-01 2025-03-31 08781493 core:FurnitureFittingsToolsEquipment 2024-04-01 2025-03-31 08781493 core:MotorVehicles 2024-04-01 2025-03-31 08781493 core:OtherPropertyPlantEquipment 2024-04-01 2025-03-31 08781493 core:Subsidiary1 2024-04-01 2025-03-31 08781493 core:Subsidiary1 1 2024-04-01 2025-03-31 08781493 core:Subsidiary2 2024-04-01 2025-03-31 08781493 core:Subsidiary2 1 2024-04-01 2025-03-31 08781493 core:Subsidiary3 2024-04-01 2025-03-31 08781493 core:Subsidiary3 1 2024-04-01 2025-03-31 08781493 core:Subsidiary4 2024-04-01 2025-03-31 08781493 core:Subsidiary4 1 2024-04-01 2025-03-31 08781493 core:Subsidiary5 2024-04-01 2025-03-31 08781493 core:Subsidiary5 1 2024-04-01 2025-03-31 08781493 core:Subsidiary6 2024-04-01 2025-03-31 08781493 core:Subsidiary6 1 2024-04-01 2025-03-31 08781493 core:UKTax 2024-04-01 2025-03-31 08781493 countries:EnglandWales 2024-04-01 2025-03-31 08781493 2024-03-31 08781493 core:RetainedEarningsAccumulatedLosses 2024-03-31 08781493 core:ShareCapital 2024-03-31 08781493 core:CurrentFinancialInstruments core:WithinOneYear 2024-03-31 08781493 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-03-31 08781493 core:Goodwill 2024-03-31 08781493 core:PatentsTrademarksLicencesConcessionsSimilar 2024-03-31 08781493 core:FurnitureFittingsToolsEquipment 2024-03-31 08781493 core:OtherPropertyPlantEquipment 2024-03-31 08781493 2023-04-01 2024-03-31 08781493 2024-03-31 08781493 bus:OrdinaryShareClass1 2024-03-31 08781493 core:RetainedEarningsAccumulatedLosses 2024-03-31 08781493 core:ShareCapital 2024-03-31 08781493 core:CurrentFinancialInstruments core:WithinOneYear 2024-03-31 08781493 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-03-31 08781493 core:Goodwill 2024-03-31 08781493 core:PatentsTrademarksLicencesConcessionsSimilar 2024-03-31 08781493 core:CostValuation 2024-03-31 08781493 core:WithinOneYear 2024-03-31 08781493 core:FurnitureFittingsToolsEquipment 2024-03-31 08781493 core:OtherPropertyPlantEquipment 2024-03-31 08781493 1 2023-04-01 2024-03-31 08781493 core:RetainedEarningsAccumulatedLosses 2023-04-01 2024-03-31 08781493 core:ShareCapital 2023-04-01 2024-03-31 08781493 core:LandBuildingsUnderOperatingLeases 2023-04-01 2024-03-31 08781493 core:Subsidiary1 1 2023-04-01 2024-03-31 08781493 core:Subsidiary2 1 2023-04-01 2024-03-31 08781493 core:Subsidiary3 1 2023-04-01 2024-03-31 08781493 core:Subsidiary4 1 2023-04-01 2024-03-31 08781493 core:Subsidiary5 1 2023-04-01 2024-03-31 08781493 core:Subsidiary6 1 2023-04-01 2024-03-31 08781493 core:UKTax 2023-04-01 2024-03-31 08781493 2023-03-31 08781493 core:RetainedEarningsAccumulatedLosses 2023-03-31 08781493 core:ShareCapital 2023-03-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 08781493

Berkeley Home Health Limited

Annual Report and Financial Statements

for the Year Ended 31 March 2025

 

Berkeley Home Health Limited

Contents

Company Information

1

Strategic Report

2

Director's Report

3

Statement of Director's Responsibilities

4

Independent Auditor's Report

5 to 7

Profit and Loss Account

8

Balance Sheet

9

Statement of Changes in Equity

10

Notes to the Financial Statements

11 to 19

 

Berkeley Home Health Limited

Company Information

Director

C Young

Registered office

Trinity Homecare Group
1-15 Central Road
Worcester Park
Surrey
KT4 8EG

Auditors

Hazlewoods LLP
Windsor House
Bayshill Road
Cheltenham
GL50 3AT

 

Berkeley Home Health Limited

Strategic Report for the Year Ended 31 March 2025

The director presents his strategic report for the year ended 31 March 2025.

Principal activity

The principal activity of the company is that of an intermediate parent company and the provision of domiciliary care services.

Fair review of the business

The results for the year, which are set out in the profit and loss account, show turnover of £3,722,000 (2024 - £5,708,000) and an operating profit before amortisation of £207,000 (2024 - £13,000). At 31 March 2025, the company had net liabilities of £6,603,000 (2024 - £703,000). The directors consider the performance for the year and the financial position at the year end to be satisfactory.

Details of future developments, principal risks and uncertainties and key performance indicators are disclosed in the group financial statements of the company's ultimate parent company, PWC Newco Limited.


Section 172 statement
The Directors believe that they have effectively implemented their duties under section 172 of the Companies Act 2006. The Company has considered the long term-strategy of the business and consider that this strategy will continue to deliver long term success to the business and its stakeholders.

The Company is committed to maintaining an excellent reputation and strives to achieve high standards. We are highly selective about the employees that we take on in order to deliver the best value to service users while also maintaining an awareness of the environmental impact of the work done, and strive to reduce carbon footprint where possible.

The Directors recognise the importance of wider stakeholders in delivering their strategy and achieving sustainability within the business. The main stakeholders in the company are considered to be the employees, suppliers and customers.

In ensuring that all stakeholders are considered as part of every decision process, we believe we act fairly between all members of the Company.

Financial instruments

Objectives and policies

The board constantly monitors the company’s trading results and revise the projections as appropriate to ensure that the company can continue to meet its future obligations as they fall due.

Price risk, credit risk, liquidity risk and cash flow risk

The company is exposed to the usual credit and cash flow risk associated with selling on credit and manages this through credit control procedures. Credit risk in respect of bank balances is safeguarded by using banks with high credit ratings.

Approved by the director on 9 December 2025


C Young
Director

 

Berkeley Home Health Limited

Director's Report for the Year Ended 31 March 2025

The director presents his report and the financial statements for the year ended 31 March 2025.

Director of the company

The director who held office during the year was as follows:

C Young

Going concern

The Director believes that the company is well placed to successfully manage its business risks and the Director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Accordingly, he continues to adopt the going concern basis of accounting in preparing the annual financial statements. See further details on going concern in note 2 to the financial statements.

Disclosure of information to the auditors

The director has taken steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the company's auditors are aware of that information. The director confirms that there is no relevant information that he knows of and of which he knows the auditors are unaware.

Reappointment of auditors

Hazlewoods LLP have expressed their willingness to continue in office.

Approved by the director on 9 December 2025


C Young
Director

 

Berkeley Home Health Limited

Statement of Director's Responsibilities

The director is responsible for preparing the Strategic Report, Directors' Report and the financial statements in accordance with applicable law and regulations.

Company law requires the director to prepare financial statements for each financial year. Under that law the director has elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the director must not approve the financial statements unless he is satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the director is required to:

select suitable accounting policies and apply them consistently;

make judgements and accounting estimates that are reasonable and prudent; and

prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The director is responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable him to ensure that the financial statements comply with the Companies Act 2006. He is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

 

Berkeley Home Health Limited

Independent Auditor's Report to the Members of Berkeley Home Health Limited

Opinion

We have audited the financial statements of Berkeley Home Health Limited (the 'company') for the year ended 31 March 2025, which comprise the Profit and Loss Account, Balance Sheet, Statement of Changes in Equity, and Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

give a true and fair view of the state of the company's affairs as at 31 March 2025 and of its loss for the year then ended;

have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and

have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the director's use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the original financial statements were authorised for issue.

Our responsibilities and the responsibilities of the director with respect to going concern are described in the relevant sections of this report.

Other information

The director are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

 

Berkeley Home Health Limited

Independent Auditor's Report to the Members of Berkeley Home Health Limited

Opinion on other matter prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

the information given in the Strategic Report and Director's Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and

the Strategic Report and Director's Report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of our knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report and the Director's Report.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or

the financial statements are not in agreement with the accounting records and returns; or

certain disclosures of director's remuneration specified by law are not made; or

we have not received all the information and explanations we require for our audit.

Responsibilities of the director

As explained more fully in the Statement of Director's Responsibilities set out on page 4, the director is responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the director determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the director is responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the director either intends to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor’s responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Extent to which the audit was capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

We considered the nature of the company’s industry and its control environment and reviewed the company’s documentation of their policies and procedures relating to fraud and compliance with laws and regulations. We also enquired of management about their own identification and assessment of the risks of irregularities.

We obtained an understanding of the legal and regulatory framework that the company operates in and identified the key laws and regulations that had a direct effect on the determination of material amounts and disclosures in the financial statements, including the UK Companies Act and tax legislation, and, those that do not have a direct effect on the financial statements but compliance with which may be fundamental to the company’s ability to operate or to avoid a material penalty.

We discussed among the audit engagement team regarding the opportunities and incentives that may exist within the organisation for fraud and how and where fraud might occur in the financial statements.

 

Berkeley Home Health Limited

Independent Auditor's Report to the Members of Berkeley Home Health Limited

In common with all audits conducted in accordance with ISAs (UK), we are also required to perform specific procedures to respond to the risk of management override of controls. In addressing the risk of fraud through management override of controls, we tested the appropriateness of journal entries and other adjustments; assessed whether the judgements made in accounting estimates are indicative of a potential bias; and evaluated the business rationale of any significant transactions that are unusual or outside the normal course of business.

In addition to the above, our procedures to respond to the risks identified included the following:

reviewing financial statement disclosures by testing to supporting documentation to assess compliance with provisions of relevant laws and regulations described as having a direct effect on the financial statements;

performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatements due to fraud;

enquiring of management concerning actual and potential litigation and claims and instances of non-compliance with laws and regulations; and

reading minutes of meetings of those charged with governance.

Our audit procedures were designed to respond to risks of material misstatement in the financial statements, recognising that the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery, misrepresentations or through collusion. There are inherent limitations in the audit procedures performed and the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we are to become aware of it.

A further description of our responsibilities is available on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report
This report is made solely to the company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company’s members as a body, for our audit work, for this report, or for the opinions we have formed.





Martin Howard (Senior Statutory Auditor)
For and on behalf of Hazlewoods LLP, Statutory Auditor

Windsor House
Bayshill Road
Cheltenham
GL50 3AT

9 December 2025

 

Berkeley Home Health Limited

Profit and Loss Account for the Year Ended 31 March 2025

Note

2025
 £ 000

2024
 £ 000

Turnover

3

3,722

5,708

Cost of sales

 

(2,376)

(3,816)

Gross profit

 

1,346

1,892

Administrative expenses

 

(1,139)

(1,879)

Operating profit before amortisation

 

207

13

Amortisation of intangible assets

 

(538)

(540)

Operating loss after amortisation

4

(331)

(527)

Other interest receivable and similar income

2

8

Amounts written off investments

11

(4,503)

-

Interest payable and similar charges

7

(1,124)

(1,132)

Loss before tax

 

(5,956)

(1,651)

Taxation

8

56

-

Loss for the financial year

 

(5,900)

(1,651)

The above results were derived from continuing operations.

The company has no recognised gains or losses for the year other than the results above.

 

Berkeley Home Health Limited

(Registration number: 08781493)
Balance Sheet as at 31 March 2025

Note

2025
 £ 000

2024
 £ 000

Fixed assets

 

Intangible assets

9

5,729

6,267

Tangible assets

10

10

29

Investments

11

8,199

12,702

 

13,938

18,998

Current assets

 

Debtors

12

418

552

Cash at bank and in hand

 

883

35

 

1,301

587

Creditors: Amounts falling due within one year

13

(21,842)

(20,288)

Net current liabilities

 

(20,541)

(19,701)

Net liabilities

 

(6,603)

(703)

Capital and reserves

 

Called up share capital

14

975

975

Profit and loss account

(7,578)

(1,678)

Total equity

 

(6,603)

(703)

Approved and authorised by the director on 9 December 2025
 


C Young
Director

 

Berkeley Home Health Limited

Statement of Changes in Equity for the Year Ended 31 March 2025

Share capital
£ 000

Profit and loss account
£ 000

Total
£ 000

At 1 April 2024

975

(1,678)

(703)

Loss for the year

-

(5,900)

(5,900)

At 31 March 2025

975

(7,578)

(6,603)

Share capital
£ 000

Profit and loss account
£ 000

Total
£ 000

At 1 April 2023

975

(27)

948

Loss for the year

-

(1,651)

(1,651)

At 31 March 2024

975

(1,678)

(703)

 

Berkeley Home Health Limited

Notes to the Financial Statements for the Year Ended 31 March 2025

 

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Trinity Homecare Group
1-15 Central Road
Worcester Park
Surrey
KT4 8EG

 

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements were prepared in accordance with Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland and the Companies Act 2006'.

Basis of preparation

These financial statements have been prepared using the historical cost convention except for, where disclosed in these accounting policies, certain items that are shown at fair value.

The company’s financial statements are presented in Sterling and all values are rounded to the nearest thousand pounds (£’000) except when otherwise indicated.

Summary of disclosure exemptions

The company has not presented a cash flow statement on the grounds that the company is a wholly owned subsidiary and a group cash flow statement is included in the financial statements of the ultimate parent company.

Name of parent of group

These financial statements are consolidated in the financial statements of PWC Newco Limited.

The financial statements of PWC Newco Limited may be obtained from Companies House.

Exemption from preparing group accounts

The company has taken advantage of the exemption in section 400 of the Companies Act 2006 from the requirement to prepare consolidated financial statements, on the grounds that it is consolidated in the above parent undertaking.

Going concern

Notwithstanding the net liability position shown on the balance sheet, the financial statements have been prepared on the going concern basis. The directors have considered the forecast cash flows and the cash requirements of the business in their assessment of going concern. As a result of this assessment it was concluded that the cash requirements of the business for the 12 months from signing will be met through a combination of operational cash flows and intergroup loans and thus the business is deemed to operate as a going concern.

 

Berkeley Home Health Limited

Notes to the Financial Statements for the Year Ended 31 March 2025

Judgements and estimation uncertainty

The preparation of financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported for assets and liabilities as the balance sheet date and the amounts reported for revenues and expenses during the period, that are not readily apparent from other sources. However, the nature of estimation means that actual outcomes may differ from those estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised and in any future periods affected.

Revenue recognition

Revenue generated from care services arranged or provided is recognised when the care has been provided. Longer care assignments not completed in the period are partially accrued for depending on care delivered in the period.

Revenue is measured at the fair value of the consideration received, excluding discounts, rebates, value added tax and other sales taxes.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in the profit and loss account, except that a charge attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements and on unused tax losses or tax credits in the company. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.

The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Furniture and equipment

25% straight line

Motor vehicles

25% straight line

Intangible assets

Goodwill arising on the acquisition of an entity represents the excess of the cost of acquisition over the company’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities of the entity recognised at the date of acquisition. Goodwill is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is held in the currency of the acquired entity and revalued to the closing rate at each reporting period date.

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class

Amortisation method and rate

Goodwill

5% straight line

Client lists

25% straight line

Computer software

25% straight line

 

Berkeley Home Health Limited

Notes to the Financial Statements for the Year Ended 31 March 2025

Business combinations

Business combinations are accounted for using the purchase method. The consideration for each acquisition is measured at the aggregate of the fair values at acquisition date of assets given, liabilities incurred or assumed, and equity instruments issued by the group in exchange for control of the acquired, plus any costs directly attributable to the business combination. When a business combination agreement provides for an adjustment to the cost of the combination contingent on future events, the group includes the estimated amount of that adjustment in the cost of the combination at the acquisition date if the adjustment is probable and can be measured reliably.

Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.

Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. All trade debtors are repayable within one year and hence are included at the undiscounted cost of cash expected to be received. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the debtors.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and all are repayable within one year and hence are included at the undiscounted amount of cash expected to be paid.

Leases

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

 

Berkeley Home Health Limited

Notes to the Financial Statements for the Year Ended 31 March 2025

Financial instruments


Classification
Financial instruments are classified and accounted for according to the substance of the contractual arrangement, as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. Where shares are issued, any component that creates a financial liability of the company is presented as a liability on the balance sheet. The corresponding dividends relating to the liability component are charged as interest expenses in the profit and loss account.

 Recognition and measurement
All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

 Impairment
Assets, other than those measured at fair value, are assessed for indicators of impairment at each balance sheet date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss as described below.

A non financial asset is impaired where there is objective evidence that, as a result of one or more events that occurred after initial recognition, the estimated recoverable value of the asset has been reduced. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use.

The recoverable amount of goodwill is derived from measurement of the present value of the future cash flows of the cash-generating units ('CGUs') of which the goodwill is a part. Any impairment loss in respect of a CGU is allocated first to the goodwill attached to that CGU, and then to other assets within that CGU on a pro-rata basis.

Where indicators exist for a decrease in impairment loss, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had no impairment been recognised. Where a reversal of impairment occurs in respect of a CGU, the reversal is applied first to the assets (other than goodwill) of the CGU on a pro-rata basis and then to any goodwill allocated to that CGU.

For financial assets carried at amortised cost, the amount of an impairment is the difference between the asset’s carrying amount and the present value of estimated future cash flows, discounted at the financial asset’s original effective interest rate.

For financial assets carried at cost less impairment, the impairment loss is the difference between the asset’s carrying amount and the best estimate of the amount that would be received for the asset if it were to be sold at the reporting date.

Where indicators exist for a decrease in impairment loss, and the decrease can be related objectively to an event occurring after the impairment was recognised, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired financial asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had no impairment been recognised.

 

Berkeley Home Health Limited

Notes to the Financial Statements for the Year Ended 31 March 2025

 

3

Turnover

The total turnover of the company has been derived from its principal activity wholly undertaken in the United Kingdom.

 

4

Operating loss

Arrived at after charging:

2025
 £ 000

2024
 £ 000

Depreciation expense

19

17

Operating lease expense - property

37

72

Amortisation of intangibles

538

540

 

5

Staff costs

The aggregate payroll costs (including director's remuneration) were as follows:

2025
 £ 000

2024
 £ 000

Wages and salaries

2,622

4,258

Social security costs

282

342

Pension costs, defined contribution scheme

61

71

2,965

4,671

Directors in the current and prior year were remunerated through a fellow group undertaking.

The average number of persons employed by the company (including the director) during the year, analysed by category was as follows:

2025
 No.

2024
 No.

Care

106

118

Administration

18

26

124

144

 

6

Auditors' remuneration

2025
£ 000

2024
£ 000

Audit of the financial statements

13

11

Other fees to auditors

All other non-audit services

4

7

 

7

Interest payable and similar expenses

2025
£ 000

2024
£ 000

Interest payable on loans from group undertakings

1,124

1,132

 

Berkeley Home Health Limited

Notes to the Financial Statements for the Year Ended 31 March 2025

 

8

Taxation

Tax credited in the profit and loss account

2025
 £ 000

2024
 £ 000

Deferred taxation

Arising from origination and reversal of timing differences

(56)

-

The tax on profit before tax for the year is higher than the standard rate of corporation tax in the UK (2024 - higher than the standard rate of corporation tax in the UK) of 25% (2024 - 25%).

The differences are reconciled below:

2025
£ 000

2024
£ 000

Loss before tax

(5,956)

(1,651)

Corporation tax at standard rate

(1,489)

(413)

Effect of expense not deductible in determining taxable profit (tax loss)

1,247

18

Movement in deferred tax not recognised

-

260

Tax (decrease)/increase from effect of capital allowances and depreciation

(53)

135

Tax increase arising from group relief

239

-

Total tax credit

(56)

-

Deferred tax

Deferred tax assets and liabilities

2025

Asset
£ 000

Fixed asset timing differences

55

Short term timing differences

1

56

 

9

Intangible fixed assets

Goodwill
 £ 000

Client lists
 £ 000

Computer software
 £ 000

Total
£ 000

Cost

At 1 April 2024 and at 31 March 2025

10,865

1,860

59

12,784

Amortisation

At 1 April 2024

4,598

1,860

59

6,517

Amortisation charge

538

-

-

538

At 31 March 2025

5,136

1,860

59

7,055

Carrying amount

At 31 March 2025

5,729

-

-

5,729

At 31 March 2024

6,267

-

-

6,267

 

Berkeley Home Health Limited

Notes to the Financial Statements for the Year Ended 31 March 2025

 

10

Tangible fixed assets

Equipment
 £ 000

Fixtures & fittings
 £ 000

Total
£ 000

Cost

At 1 April 2024 and at 31 March 2025

94

98

192

Depreciation

At 1 April 2024

94

69

163

Charge for the year

-

19

19

At 31 March 2025

94

88

182

Carrying amount

At 31 March 2025

-

10

10

At 31 March 2024

-

29

29

 

11

Investments

2025
£ 000

2024
£ 000

Investments in subsidiaries

8,199

12,702

Subsidiaries

£ 000

Cost and carrying amount

At 1 April 2024 and at 31 March 2025

12,702

Provision

Provision during the year and at 31 March 2025

4,503

Carrying amount

At 31 March 2025

8,199

At 31 March 2024

12,702

Details of undertakings

Details of the investments (including principal place of business of unincorporated entities) in which the company holds 20% or more of the nominal value of any class of share capital are as follows:

Undertaking

Registered office

Principal activity

Proportion of voting rights and shares held

2025

2024

Subsidiary undertakings

Corinium Care Limited

England and Wales

Care services

100%

100%

Fitzrovia Personal Homecare Limited

England and Wales

Intro. services

100%

100%

Care Your Way Investments Limited

England and Wales

Dormant

100%

100%

Berkeley Northwood Limited

England and Wales

Care services

100%

100%

Berkeley Winchmore Hill Ltd

England and Wales

Care services

100%

100%

Berkeley Surrey Limited

England and Wales

Care services

100%

100%

 

Berkeley Home Health Limited

Notes to the Financial Statements for the Year Ended 31 March 2025

All shares held are ordinary shares.

All shares are held directly with the exception of Berkeley Surrey Limited.

All subsidiary undertakings are registered at the same address as the company.

 

12

Debtors

Note

2025
 £ 000

2024
 £ 000

Trade debtors

 

93

117

Other debtors

 

4

16

Prepayments and accrued income

 

265

419

Deferred tax assets

8

56

-

   

418

552

 

13

Creditors

2025
 £ 000

2024
 £ 000

Due within one year

Trade creditors

9

53

Amounts due to group undertakings

21,377

19,855

Social security and other taxes

139

62

Outstanding defined contribution pension costs

11

24

Accruals

241

229

Deferred income

65

65

21,842

20,288

Amounts due to group undertakings include a loan of £11.4m (2024 - £10.9m) which incurs interest at a rate of 10% and is repayable on demand. The remaining amounts owed to group companies are interest free and repayable on demand.

 

14

Share capital

Allotted, called up and fully paid shares

 

2025

2024

 

No.

£

No.

£

Ordinary shares of £1 each

975,000

975,000

975,000

975,000

         
 

15

Pension schemes

Defined contribution pension scheme

The company operates a defined contribution pension scheme. The pension cost charge for the year represents contributions payable by the company to the scheme and amounted to £61,000 (2024 - £71,000).

Contributions totalling £11,000 (2024 - £24,000) were payable to the scheme at the end of the year and are included in creditors.

 

Berkeley Home Health Limited

Notes to the Financial Statements for the Year Ended 31 March 2025

 

16

Operating lease commitments

The total of future minimum lease payments is as follows:

2025
£ 000

2024
£ 000

Not later than one year

11

28

 

17

Related party transactions

The company has taken advantage of the exemption under paragraph 33.1A of FRS 102 not to disclose transactions with fellow wholly owned subsidiaries.

The total remuneration of directors, who are considered key management for the purposes of disclosure, in the year ended 31 March 2025 (including salaries and other benefits) is disclosed in note 5 of the financial statements.

 

18

Contingent liabilities

The company is bound by an intra-group cross guarantee (which is secured over the company's trade and assets) in respect of bank debt with other members of the group headed by PWC Holdco 1 Limited. At 31 March 2025, the amount guaranteed is £29.889m (2024 - £32.586m).

 

19

Parent and ultimate parent undertaking

The company's immediate parent is Berkeley Home Health Holdco Limited, incorporated in England and Wales.

 The ultimate parent is PWC Newco Limited, incorporated in England and Wales.

The most senior parent entity producing publicly available financial statements is PWC Newco Limited. These financial statements are available upon request from Companies House.

The ultimate controlling party is Limerston Capital LLP.